Comparison of generic (Rolexan) and brand (Clexan) forms of enoxapari
Phase 4
- Conditions
- Prophylaxis of deep vein thrombosis.Phlebitis and thrombophlebitis of other deep vessels of lower extremities
- Registration Number
- IRCT2016031910178N9
- Lead Sponsor
- Ronak Pharm
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Age 18 years and older; Receiving enoxaparin with prophylactic dose
Exclusion criteria: Patient participating in another study; Pregnant or lactating; Taking an anticoagulant in the last three months; Contraindication absolute and / or relative to the use of enoxaparin; Nobody wishing to participate in this study; Creatinine clearance less than 60ml/min
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Measurment of anti Xa activity. Timepoint: Before and 4 hour after receiving enoxaparin. Method of measurement: Kit.
- Secondary Outcome Measures
Name Time Method